Advanced Filters
noise

neoplasms Clinical Trials

A listing of neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 14,282 clinical trials
P Peter Ka-Fung CHIU, FRCS, PhD

Artificial Intelligence (AI)-Assisted Risk-based Prostate Cancer Detection

This is a prospective clinical study recruiting 510 men at risk of PCa to undergo urine, blood, AI-assisted ultrasound and AI-assisted MRI investigations to stratify risk of clinically significant PCa (csPCa). (sample size calculation in section 5)

18 years of age Male Phase N/A
K Kunal Jana, MD

Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program

Each year over 20,000 men are diagnosed with prostate cancer in Canada with the majority undergoing some form of treatment option. Radical prostatectomy and/or radiation therapy are common procedures that are effective in the treatment of prostate cancer. However, they typically incur both short- and long-term side effects (e.g. urinary …

18 years of age Male Phase N/A
J Jonathan Abele, MD

18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028

A two-centre prospective cohort phase III study of 18F-PSMA-1007 PET/CT imaging in specific patient populations: Adults patients (≥18 years old) with a history of radical prostatectomy for treatment of prostate cancer, and a serum prostate specific antigen (PSA) ≥ 0.2 mcg/L Adult patients with a history of radiotherapy, cryotherapy, or …

18 years of age Male Phase 3
K Kellie Bodeker, Ph.D.

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

The purpose of this study is to determine whether \[225Ac\]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of standard of care (SOC) (ARPI change …

18 - 100 years of age Male Phase 3
H Hongqian Guo, Phd

Diagnostic Value of MRI-targeted Plus Index-lesion-ipsilaterally Systematic Biopsy for Biopsy-naive Men At Risk of Prostate Cancer

Targeted and systematic biopsy stands as the prevalent diagnostic approach for prostate cancer. Despite its widespread use, this method is characterized by a high volume of needle biopsies. A refined approach, termed targeted and index-lesion-ipsilateral systematic biopsy, as one of targeted and regional systematic biopsy methods, aim to reduce the …

60 - 80 years of age Male Phase N/A
G Giulia Sorgentoni, PhD

ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa

Study wants to explore real-world data in three distinct settings Patients with metachronous or de novo mCSPC treated with ADT+ARSI or ADT+ARSI+docetaxel \_ARON-3S Patients receiving Lutetium-177 PSMA for mCRPC \_ ARON-3Lu Patients treated with PARP inhibitors (alone or combined with ARSI) for CRPC \_ ARON-3GEN

18 years of age All Phase N/A
D Dora Meikle

The PROSECCA Study, Answering New Questions in Prostate Cancer

Nearly half of all cancer patients receive radiotherapy as part of their treatment and although it is effective at destroying cancerous lesions deep within the body, this comes at the cost of damaging healthy, or normal, tissues. With 50% of cancer patients surviving for 10 years or more, these patients …

years of age Male Phase N/A
P Peter Ka-Fung CHIU, FRCS, PhD

Comparing MRI-Ultrasound Fusion and Cognitive-guided Biopsy for the Detection of csPCa: the PROFUSION Trial

This study is an international multicentre RCT to compare the linically significant prostate cancer (csPCa) detection of cognitive-guided and MRI-USG guided biopsies in men with suspicious MRI lesion.

18 years of age Male Phase N/A
L Luke Arsenault

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA targeted therapy. Treatment of interest: the investigational treatment is AAA817 regardless of subsequent anti-neoplastic treatment. The control treatment …

18 - 100 years of age Male Phase 2/3
V Vera Sweere, MD

Sequential Imaging of Suspicion of Prostate Cancer Reducing Overdiagnosis and Unnecessary Biopsy With Timely Diagnosis of Significant Cancer

The goal of this clinical trial is to evaluate the safety and effectiveness of a novel diagnostic strategy for prostate cancer, in which men with a moderate risk of prostate cancer are monitored using PSA and MRI instead of immediate biopsy,. The main questions it aims to answer are: Is …

18 years of age Male Phase N/A

Simplify language using AI